Impel Pharmaceuticals Announces Strategic Reprioritization,
Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 PercentCompany will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales...
Source: globenewswire.com
Page 3 - Nasdaq Impl News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Impl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Impl Today - Breaking & Trending Today
Impel Pharmaceuticals to Participate in Guggenheim 4th
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative...
Source: globenewswire.com
Impel NeuroPharma (IMPL) and The Competition Critical Contrast
Impel NeuroPharma (NASDAQ:IMPL – Get Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Impel NeuroPharma to similar companies based on the strength of its valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Analyst Ratings This is […]
Source: etfdailynews.com
Impel NeuroPharma (IMPL) vs. The Competition Head to Head Survey
Impel NeuroPharma (NASDAQ:IMPL – Get Rating) is one of 937 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Impel NeuroPharma to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership. Profitability This table compares Impel NeuroPharma […]
Source: etfdailynews.com
Impel NeuroPharma (NASDAQ:IMPL) Posts Earnings Results, Misses Expectations By $0.21 EPS
Impel NeuroPharma (NASDAQ:IMPL – Get Rating) released its quarterly earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.21), MarketWatch Earnings reports. IMPL stock opened at $7.52 on Friday. Impel NeuroPharma has a twelve month low of $5.72 and a twelve month high […]
Source: etfdailynews.com